TriangleNCT02048371 · OUTCOME
Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 16 weeks
What was measured
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort C (Ewing/Ewing-like sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
Groups in this outcome
Cohort C: Ewing Sarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Cohort D: Rhabdomyosarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Cohort E: Mesenchymal Chondrosarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
| Group | Source count |
|---|---|
| Cohort C: Ewing Sarcoma | 30 |
| Cohort D: Rhabdomyosarcoma | 10 |
| Cohort E: Mesenchymal Chondrosarcoma | 1 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort C: Ewing Sarcoma | 3.4 | Not reported | 1.7 | 3.7 | Not reported |
| Cohort D: Rhabdomyosarcoma | 1.82 | Not reported | 1.58 | NA | The upper limit of the CI is below the level of detection. |
| Cohort E: Mesenchymal Chondrosarcoma | NA | Not reported | NA | NA | There is only one participant, so statistics cannot be calculated. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.7
- upper Limit
- 3.7
- value
- 3.4
- comment
- The upper limit of the CI is below the level of detection.
- group Id
- OG001
- lower Limit
- 1.58
- upper Limit
- NA
- value
- 1.82
- comment
- There is only one participant, so statistics cannot be calculated.
- group Id
- OG002
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 30
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 1
- units
- Participants
- description
- The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort C (Ewing/Ewing-like sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
- id
- OG000
- title
- Cohort C: Ewing Sarcoma
- description
- Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
- id
- OG001
- title
- Cohort D: Rhabdomyosarcoma
- description
- Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
- id
- OG002
- title
- Cohort E: Mesenchymal Chondrosarcoma
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- up to 16 weeks
- title
- Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice